Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ALXO
ALXO logo

ALXO Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy ALX Oncology Holdings Inc (ALXO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.530
1 Day change
5.52%
52 Week Range
2.660
Analysis Updated At
2026/06/18
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

ALX Oncology Holdings Inc (ALXO) is not a good buy for a beginner, long-term investor at this time. The technical indicators, options data, insider trading trends, and lack of positive catalysts suggest a weak outlook for the stock. Additionally, the absence of recent financial data, analyst ratings, or significant news further diminishes the case for investment.

Technical Analysis

The technical indicators are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 46.744, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support is at 1.406, and resistance is at 1.608. The stock's recent price movement shows limited upside potential.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The implied volatility is extremely high at 626.63, with an IV percentile of 99.6, indicating significant uncertainty. The low put-call ratios suggest limited bullish sentiment.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
7

Positive Catalysts

  • NULL identified. There is no recent news, no AI Stock Picker or SwingMax signals, and no positive insider or institutional trading trends.

Neutral/Negative Catalysts

  • Insiders are selling heavily, with a 2135% increase in selling activity over the last month. Technical indicators are bearish, and there is no recent congress trading data or news to support a positive outlook.

Financial Performance

No financial data is available for analysis due to an error in the provided data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available for ALXO.

Wall Street analysts forecast ALXO stock price to rise
4 Analyst Rating
Wall Street analysts forecast ALXO stock price to rise
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.450
sliders
Low
2
Averages
3.33
High
4
Current: 1.450
sliders
Low
2
Averages
3.33
High
4
Wells Fargo
Overweight
initiated
$5
AI Analysis
2026-03-19
Reason
Wells Fargo
Price Target
$5
AI Analysis
2026-03-19
initiated
Overweight
Reason
Wells Fargo initiated coverage of ALX Oncology with an Overweight rating and $5 price target. The firm thinks the near-term update for the evorpacept plus zanidatamab combo in metastatic breast cancer will further validate ALX's CD47-high enrichment strategy. Wells says the update will de-risk the ASPEN-Breast readout in mid-2027. It likes the setup for ALX shares.
H.C. Wainwright
Swayampakula Ramakanth
maintain
$2 -> $4
2026-03-10
Reason
H.C. Wainwright
Swayampakula Ramakanth
Price Target
$2 -> $4
2026-03-10
maintain
Reason
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on ALX Oncology to $4 from $2 and keeps a Buy rating on the shares. The firm says the next major catalyst for the shares is the ALX2004 safety data in the second half of 2026. There is potential for ALX2004 to be different from other EGFR antibody-drug conjugates in terms of safety, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ALXO
Unlock Now

People Also Watch